Wilbur Chen

Adult infectious disease physician-scientist with a passion to solve global health problems through safe and effective vaccines. Opinions my own.

[Wilbur Chen @Wilburchenmd]

Our Nature Medicine paper received Clinical Publication of the Year award. This combination typhoid and non-typhoidal Salmonella vaccine is an invention of CVD investigators.

[Wilbur Chen @Wilburchenmd]

@JIDJournal This publication received "Editor's Choice" and represents decades long research by Dr. Eileen Barry on developing a combined Shigella-ETEC vaccine.

[Journal of Infectious Diseases @JIDJournal]

First-in-Human Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated Shigella flexneri 2a Live Vector Expressing Enterotoxigenic Escherichia coli Antigens, Vaccine Strain CVD 1208S-122

✅ Just Accepted
✍️ @wilburchenmd
🔗 https://t.co/5xXT0w3Dcu

[Wilbur Chen @Wilburchenmd]

Check out Dr. Justin Ortiz's publication on a Lassa fever vaccine, hitchhiking on a rabies vaccine. Kudos to the scientists at the Center for Vaccine Development and Global Health and at Sidney Kimmel Medical College. https://t.co/5xAQjUOriz

[Wilbur Chen @Wilburchenmd]

Huge congrats to Likak Research on 15 years of supporting clinical research in West and Central Africa! Honored by their "Outstanding Partner" award, but Likak is the real MVP.

[Wilbur Chen @Wilburchenmd]

The CVD's own combined typhoid and non-typhoidal Salmonella vaccine was evaluated in a second trial and recently published in The Journal of Infectious Diseases.
https://t.co/G195hTN1j9

[Wilbur Chen @Wilburchenmd]

The CVD's own combined Shigella-ETEC vaccine was evaluated in a Phase 1 study and recently published in The Journal of Infectious Diseases (Editor's Choice).
https://t.co/ohthKX5FEr

[Wilbur Chen @Wilburchenmd]

Last week the NmCV-5 EPI Study Team received the 2026 Best Publication Award from the NIAID-supported IDCRC for our publication in The Lancet last year. I want to highlight how this award confirms the excellence of my colleagues @CVDMali @ProfessorSow.
https://t.co/co7U7vCyyH

[Wilbur Chen @Wilburchenmd]

This article represents the first look at the safety and robust immunogenicity of our combined typhoid and non-typhoidal Salmonella vaccine.
https://t.co/Gp1BM8RGRK

[Wilbur Chen @Wilburchenmd]

https://t.co/mWJXqccCzM

[Wilbur Chen @Wilburchenmd]

Listen to my discussion with Ed Butch on advice regarding health essentials for international travel with study abroad experiences.
From Campus to Global Classroom: Health Essentials for Study Abroad - On Campus Podcast

[Wilbur Chen @Wilburchenmd]

Listening to "A Conversation With Dr. Wilbur Chen on Federally Funded Research and Global Health" at https://t.co/gS6VRV1cmN

[Wilbur Chen @Wilburchenmd]

Listen to Research Ethics Reimagined, Human Challenge Studies.
https://t.co/9ul4QO0EsX

[Wilbur Chen @Wilburchenmd]

NFID Announces 2025-2026 Board of Directors https://t.co/4sgZkSgxeu

[Wilbur Chen @Wilburchenmd]

I am honored to continue to advocate for the value of vaccines through NFID. I am looking forward to working with terrific colleagues who are like-minded in protecting the public.

NFID Announces 2025-2026 Board of Directors

[Wilbur Chen @Wilburchenmd]

Our Center’s very own, Dr Justin Ortiz, is leading this important study.

https://t.co/sOw5AykAsw

[Wilbur Chen @Wilburchenmd]

Listening to "A Conversation With Dr. Wilbur Chen on Federally Funded Research and Global Health" at https://t.co/gS6VRV1cmN

[Wilbur Chen @Wilburchenmd]

Kudos for CVD-Mali!
The Lancet https://t.co/co7U7vCyyH

[Wilbur Chen @Wilburchenmd]

Check out our publication on Shigella bacteriophage.
Antibiotics | Free Full-Text | Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial (https://t.co/9np1kboDTd)

[Wilbur Chen @Wilburchenmd]

@januarypayne @NIHClinicalCntr @nih_nhlbi @NIAIDNews @rarediseasesnet January, glad you are doing well and making your life’s trials an inspiration to others!